BLUESKY TECHNOLOGY PARTNERS ANNOUNCES NAME CHANGE TO BLUESKY COMMERCE

BlueSky Technology Partners, a leading e-commerce solutions provider, announced today that the company will be operating under a new name, BlueSky Commerce.

From its inception, BlueSky has been on the cutting edge, leveraging our partnerships to provide e-commerce solutions. Our expertise has grown to more than shopping carts and checkout experiences.”

— Todd Irwin, Co-Founder and CEO

NOBLESVILLE, INDIANA, UNITED STATES, October 20, 2020 /EINPresswire.com/ — BlueSky Technology Partners, a leading e-commerce solutions provider for over 15 years, proudly announced today that the company will be operating under a new name, and will be known as BlueSky Commerce. This name and new branding initiative stems from the organization’s expansion of its capabilities and solutions. In addition to its globally recognized technology services, the company has grown to help companies achieve their business goals with creative and marketing services, staffing and talent acquisition services as well as strategic consultancy services.

Co-founder and CEO, Todd Irwin, says this name change is a nod to the fact that today’s commerce solutions go far beyond just technology.

“From its inception, BlueSky has been on the cutting edge,” Irwin says, “leveraging our industry partnerships to provide customized technology platform solutions to all types of businesses. Over the years, our expertise has grown to be way more than shopping carts and checkout experiences. We offer an entire menu of business solutions to help companies of all sizes achieve their business goals and we wanted a name that speaks to that.”

BlueSky Commerce’s 360 Approach allows its consultants and strategists to offer clients and prospects a holistic view of their own operations while providing a multifaceted roadmap to achieving revenue and growth goals. Each operating unit within the agency (Strategy, Technology, Marketing, and Talent Acquisition) can operate autonomously to provide services and it can work in tandem with some or all of the other units to bring an added level of value.

BlueSky Commerce’s Chief Strategy Officer, Kevin Lyons, offers a view from not only the internal strategic level, but being on the client-side in senior leadership for over 25 years. In fact, he was a BlueSky client while he led a major retailer’s e-Commerce Division during their explosive digital growth over the three-plus-year partnership with BlueSky.

“BlueSky was instrumental in helping our company achieve exponential online growth. They provided more than technology solutions; they took our digital transformation to a whole new level. I experienced firsthand the direct impact BlueSky Commerce has on driving results from the client-side and now in a leadership role with BlueSky Commerce. These results are due to BlueSky living the philosophy that growth in today’s digitally connected world is more than technology. It is understanding our clients’ business and organizational goals while gaining a deep understanding of our clients’ customers and their overall paths to purchase.”

About BlueSky Commerce
BlueSky is a professional services company that provides a full range of business strategy, technology, marketing, and talent to clients worldwide. With more than fifteen years of experience taking enterprise-level retail, consumer products, government, life sciences, and healthcare organizations to new heights, our 360 approach with our clients has a strong track record of diversified revenue streams and solutions that promote sustainable and scalable growth. BlueSky Commerce is headquartered in Noblesville, Indiana with global business units in Toronto Canada, and Hyderabad, India.
For more information visit www.blueskycommerce.io.

Lori Winkler
BlueSky Commerce
+1 317-213-8046
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

HVPCI reports “98” and marks six-month milestone of patient monitoring amid COVID-19 pandemic

Patient Confidence Index - from COVID-19 Onset to Today

Patient Confidence Index – from COVID-19 Onset to Today

HVPCI reports “98”

HVPCI reports “98”

HealthVerity announced the most recent update to its HealthVerity Patient Confidence Index (HVPCI) and reported a national score of 98, a three-point increase.

Countering the positive uptick for most specialties is the trend seen for oncology (88) which reported the lowest score since late June 2020.”

— HealthVerity

PHILADELPHIA, PA, UNITED STATES, October 20, 2020 /EINPresswire.com/ — HealthVerity announced the most recent update to its HealthVerity Patient Confidence Index (HVPCI) and reported a national score of 98, a three-point increase from the previous period and the highest level to date. After 6 months of reporting on patient confidence in returning to traditional doctor’s visits in light of the pandemic, this score reflects the sixth index to fall within “stable” levels noting a continued positive pattern for US patients seeking care across all major therapeutic areas.

The HVPCI represents a measure of physician visits undertaken by non-COVID-19 patients across 20 key therapeutic areas, highlighting a significant decline in visits since the pandemic took hold in the US at the beginning of March. The HVPCI is crucial as an expression of the confidence in patients to seek care for acute and chronic illnesses balanced with the risk of exposure to the coronavirus in a public setting. As coronavirus cases peak and eventually subside, this indicator will ultimately serve as an overall measure of US patient engagement between patients and their physicians.

This period’s national score of 98 not only reflects the highest score to date since the onset of COVID-19, but also marks the first time that five of the major specialties see patient engagement above or meeting the “normal” threshold of 100. Family and general practice (100), gastrointestinal and genitourinary (GI & GU) (109), infectious disease (116), pediatrics (115) and preventive med (110) all rendered scores higher than last period, but only infectious disease is surpassing the rates of 2019.

Countering the positive uptick for most specialties is the trend seen for oncology (88) which reported the lowest score since late June 2020. This score and the negative decline seems to further prove the issue of many Americans avoiding oncology screenings and other cancer-related lifesaving procedures amid the pandemic. “There’s really almost no way that doesn’t turn into increased mortality,” with the full effects likely to play out over a decade, said Norman E. “Ned” Sharpless, director of the National Cancer Institute. Missed screenings and other pandemic-related impacts on care could result in about 10,000 additional deaths from breast and colon cancer alone over the next 10 years, the NCI projected earlier this year. Dr. Sharpless said the estimate now appears low.

Telehealth visits declined for the tenth straight period with total share of visits at its lowest to date, accounting for only 8%. At the height of the pandemic, telehealth visits hovered around 20% compensating for the lack of willingness by patients to attend their doctor’s visits in person. Endocrinology, pulmonology and rheumatology represent the areas where telehealth still remains at an elevated level especially for patients within the age groups of 51-64 and 64+. As mentioned in the last couple of index reports, the colder weather and unfortunate drift into flu season may again elevate telehealth at levels seen in April and May of this year, but only the data will tell.

Learn more about HealthVerity’s efforts to educate and inform on COVID-19 here.

Abby Stockwell
HealthVerity
+1 8565627413
astockwell@healthverity.com
Visit us on social media:
LinkedIn


Source: EIN Presswire

Healthcare IT Market Growth Analysis and Technology Advancement by Key Industry Players for 2021

Healthcare IT market

Healthcare IT market

Healthcare IT market is expected to grow due high demand for cost effective treatments and reduction in costs associated to healthcare.

PUNE, MAHARASHTRA, INDIA, October 20, 2020 /EINPresswire.com/ — The Healthcare Information Technology solutions & services defined in this report automate, manage, and control the different tasks and processes in healthcare organizations. healthcare IT market growth is attributed to the rising demand for patient safety & data accuracy, need to curtail healthcare cost, and implementation of various healthcare policies promoting the use of HCIT in healthcare facilities.

Healthcare information technology is a field of IT that involves the design, creation, development, use, and maintenance of information systems for the healthcare industry. Automatic and interoperable healthcare information systems offer a host of advantages such as low costs, minimal errors, improved medical care and public health, enhanced efficiency, and better patient satisfaction. The U.S. Health Care Information Technology (HCIT) market was evaluated at $61,018 million in 2017, and is estimated to reach $149,178 million by 2025, at a CAGR of 11.7% during the forecast period.

Download Free Sample PDF of Report: https://www.alliedmarketresearch.com/request-sample/472

Healthcare IT market is driven by growing demand for improved patient safety and patient care as well as increase in government initiatives to promote HCIT. However, the U.S. HCIT is a well-established market and thus, there is a huge supply and demand gap with many local as well as international key players operating in this segment. This factor is expected to hamper the market growth. Moreover, numerous key players have collaborated with local players for developing efficient products to create lucrative opportunities in the market.

Among healthcare provider solutions, the clinical solutions segment dominated the market accounting for half share of the market in 2017. This was attributed to the increase in IT integration and rise in demand for clinical solutions in the healthcare industry.

Among end users, the healthcare providers segment dominated the market in 2017 accounting for two-thirds share of the total market. This is owing to the increase in demand for data accuracy to ensure patient safety through improved clinical outcomes, rise in healthcare reforms, and efforts to curb the healthcare expenditure.

Healthcare providers and hospitals segments dominated the market accounting for about two-thirds share of the total market as hospitals includes several applications such as EMR, CPOE, RIS, medical document management system, revenue cycle management, and healthcare asset management system.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/472

The leading players in global healthcare information technology market have focused on expanding their presence in the Asia-Pacific region through expansions, acquisitions, and agreements. Thus, increasing investment by leading players in the region coupled with investments from central & local government agencies creates significant growth opportunities for healthcare IT market. Key players profiled in this report include McKesson Corporation (U.S.), United Healthcare Group(U.S.), Allscripts Healthcare Solutions, Inc. (U.S.), Athenahealth, Inc. (U.S.), Epic Systems Corporation (U.S.), GE Healthcare (UK), Cerner Corporation (U.S.), Oracle Corporation (U.S.), Koninklijke Philips N.V. (The Netherlands), Infor, Inc. (U.S.), *Other players in the value chain include Wolters Kluwer, IBM, 3M health Information Systems, Conifer Health Solutions, Kronos Incorporated, Anthelio Healthcare Solutions Inc., Lexmark Healthcare, Orian Health, Wipro Technologies, CSI Healthcare IT, Syntel Inc., and Spok Inc.

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

Shadab Pathan
Allied Market Research
+1 800-792-5285
email us here


Source: EIN Presswire

Global Asthma Drugs Market 2020 Industry Analysis, Size, Share, Growth, Trends & Forecast To 2026

New Study Reports “Asthma Drugs Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026” has been Added on WiseGuyReports.

PUNE, MAHARASTRA, INDIA, October 20, 2020 /EINPresswire.com/ — Asthma Drugs Market 2020-2026

New Study Reports “Asthma Drugs Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026” has been Added on WiseGuyReports.

Report Summary:-

The Global Asthma Drugs Market Report 2020-2026 (Forecast Period) Offers An In-Depth Study Of Market Growth Factors, Future Evaluation, Country-Level Analysis, Asthma Drugs Market Distribution, And Competitive Landscape Study Of Significant Industry Players. Every Segment Of The Global Asthma Drugs Market Is Extensively Assessed In The Research Report. The Segment Analysis Offers Critical Opportunities Available In The Global Asthma Drugs Market Through Leading Segments. The Regional Study Of The Global Asthma Drugs Market Helps Readers To Attain A Thorough Understanding Of The Developments Of The Different Geographic Markets In Recent Years And Also Going Forth. In Addition, The Report Provides A Comprehensive Overview Of The Vital Dynamics Of The Global Asthma Drugs Market, Including Market Influence And Market Effect Factors, Drivers, Threats, Constraints, Trends, And Prospects. The Research Study Also Contains Other Forms Of Analysis, Such As Qualitative And Quantitative.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Asthma Drugs Market Share Analysis
Asthma Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Asthma Drugs business, the date to enter into the Asthma Drugs market, Asthma Drugs product introduction, recent developments, etc.
The major vendors covered:
Pfizer
GlaxoSmithKline
Novartis
Merck
Boehringer Ingelheim
AstraZeneca
Roche
Teva Pharmaceutical
Vectura Group

Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/5922159-global-and-china-asthma-drugs-market-insights-forecast-to-2026

Market Dynamics:-

The report also examines the several volume trends, the pricing history, and the market value in addition to understanding the key dynamics of the Asthma Drugs market. Several future growth drivers, challenges, and opportunities are also analyzed to obtain a better view of the industry.

Asthma Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Asthma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Asthma Drugs market is segmented into
Quick-relief Medications (Rescue Medications)
Medications for Allergy-induced Asthma

Segment by Application, the Asthma Drugs market is segmented into
Allergic Asthma
Non-Allergic Asthma

Regional and Country-level Analysis
The Asthma Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Asthma Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

Ask Any Query @ https://www.wiseguyreports.com/enquiry/5922159-global-and-china-asthma-drugs-market-insights-forecast-to-2026

If you have any special requirements, please let us know and we will offer you the report as you want.

Regional Analysis:-

Geographically, the report covers research on production, consumption, revenue, market share and growth rate, and the 2020-2026 forecast for the following regions: North America, Europe, Asia-Pacific, South America, Middle East, and Africa.

Major Key Points from Table of Content:

1 Study Coverage
1.1 Asthma Drugs Product Introduction
1.2 Market Segments
1.3 Key Asthma Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Asthma Drugs Market Size Growth Rate by Type
1.4.2 Quick-relief Medications (Rescue Medications)
1.4.3 Medications for Allergy-induced Asthma
1.5 Market by Application
1.5.1 Global Asthma Drugs Market Size Growth Rate by Application
1.5.2 Allergic Asthma
1.5.3 Non-Allergic Asthma
1.6 Study Objectives
1.7 Years Considered

……

12 Company Profiles
12.1 Pfizer
12.1.1 Pfizer Corporation Information
12.1.2 Pfizer Description and Business Overview
12.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Pfizer Asthma Drugs Products Offered
12.1.5 Pfizer Recent Development
12.2 GlaxoSmithKline
12.2.1 GlaxoSmithKline Corporation Information
12.2.2 GlaxoSmithKline Description and Business Overview
12.2.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
12.2.4 GlaxoSmithKline Asthma Drugs Products Offered
12.2.5 GlaxoSmithKline Recent Development
12.3 Novartis
12.3.1 Novartis Corporation Information
12.3.2 Novartis Description and Business Overview
12.3.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Novartis Asthma Drugs Products Offered
12.3.5 Novartis Recent Development
12.4 Merck
12.4.1 Merck Corporation Information
12.4.2 Merck Description and Business Overview
12.4.3 Merck Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Merck Asthma Drugs Products Offered
12.4.5 Merck Recent Development
12.5 Boehringer Ingelheim
12.5.1 Boehringer Ingelheim Corporation Information
12.5.2 Boehringer Ingelheim Description and Business Overview
12.5.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Boehringer Ingelheim Asthma Drugs Products Offered
12.5.5 Boehringer Ingelheim Recent Development
12.6 AstraZeneca
12.6.1 AstraZeneca Corporation Information
12.6.2 AstraZeneca Description and Business Overview
12.6.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
12.6.4 AstraZeneca Asthma Drugs Products Offered
12.6.5 AstraZeneca Recent Development
12.7 Roche
12.7.1 Roche Corporation Information
12.7.2 Roche Description and Business Overview
12.7.3 Roche Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Roche Asthma Drugs Products Offered
12.7.5 Roche Recent Development
12.8 Teva Pharmaceutical
12.8.1 Teva Pharmaceutical Corporation Information
12.8.2 Teva Pharmaceutical Description and Business Overview
12.8.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Teva Pharmaceutical Asthma Drugs Products Offered
12.8.5 Teva Pharmaceutical Recent Development
12.9 Vectura Group
12.10 Pfizer

Continued…..

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Contact US:

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

NORAH TRENT
WiseGuy Research Consultants Pvt. Ltd.
08411985042
email us here


Source: EIN Presswire

RNA Therapeutics 2021 is now a virtual conference

RNA Therapeutics 2021

RNA Therapeutics 2021

SMi Reports: The 2021 conference is now a virtual conference: Online access only. Explore Innovations in technologies and applications of RNA-based medicine.

LONDON, KENSINGTON, UNITED KINGDOM, October 20, 2020 /EINPresswire.com/ — Join us in February 2021, as SMi’s 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry, upcoming regulatory updates and industry implications.

BENEFITS OF ATTENDING THE VIRTUAL CONFERENCE:

• Live and On Demand speaker content: Get access to the latest strategies and case studies from your marketplace online!
• Network with all the event attendees: Connect, see who’s attending, chat and share contact details with all online delegates, speakers and sponsors
• Exhibit a Virtual Booth: You can pack your customized booth full of documents, videos and even show who is manning the booth during the event and hosting meetings
• Host & Join Meetings & Socials: Join preferred speaking sessions, host you own meetings and even a virtual Networking social, with in built Zoom functionality

Registration is live on the website and free to all pharma and biotech companies. Commercial rate only: £499. Register online: www.therapeutics-rna.com/einpr2

Delegates stand to gain many valuable insights from this event such as:
• Industry insights into how mRNA is being used to combat COVID-19
• Case studies exploring the growing therapeutic potential of RNA for rare diseases
• Future trends in AI application for optimal RNA therapeutics
• A regulatory outlook of the RNA landscape, clinical trials and looking ahead

View the full agenda and speaker line-up here: www.therapeutics-rna.com/einpr2

Proudly sponsored by: Thermo Fisher Scientific

— ENDS –

Contact Information:
For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smi-online.co.uk

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
02078276088
email us here


Source: EIN Presswire

Critical Care Therapeutics 2020 Global Market Outlook,Research,Trends And Forecast To 2025

WiseGuyReports.Com Publish a New Market Research Report On –“ Critical Care Therapeutics 2020 Global Market Outlook,Research,Trends And Forecast To 2025”.

PUNE, MAHARASTRA, INDIA, October 20, 2020 /EINPresswire.com/ —

Critical Care Therapeutics Market 2020

Description: –

Critical care or intensive care is the close monitoring and treatment given to individuals with acute, life-threatening illness or injuries such as shock, burns, accidents, complicated surgeries, sepsis, and severe breathing problems. It usually takes place in an ICU or trauma center. Plasma is the fluid portion of the blood, in which all the blood cells are suspended. It makes up about 55% of the total volume of the blood. The other components such as red blood cell (RBC), white blood cell (WBC), and platelets together comprise the remaining 45% of the blood. Plasma is mainly made up of water, which accounts for about 91% of the total volume.

The analysts forecast the global critical care therapeutics market to grow at a CAGR of 3.62% during the period 2017-2021.

The global markets are a very unstable and unpredictable environment, which needs careful assessment and understanding. The global Critical Care Therapeutics market requires appropriate and timely research to survive the overpopulated market and escape the challenges with smart working. This report will cover all the major aspects of the market like competition, technological developments, pros & cons, regional analysis, openings, etc. This report will also cover historical importance points while uncovering the market from 2020 to 2025 and will define the yearly growth rates during this tenure. This report also defines the annual growth of the market during this period.

Get a Free Sample Report @ https://www.wiseguyreports.com/sample-request/1237686-global-critical-care-therapeutics-market-2017-2021

For more information or any query mail at sales@wiseguyreports.com

Major Key Company Profiles included are :-

• CSL Behring
• Grifols
• Kedrion Biopharma
• Octapharma
• Shire

Other prominent vendors
• Abeona Therapeutics
• ADMA Biologics
• Albumedix
• Armetheon
• Asklepios BioPharmaceutical
• Aspen Pharma
• Baxter
• Bayer HealthCare
• Bio Products Laboratory
• BioDelivery Sciences
• Biogen Idec
• BioMarin
• Biotest Pharmaceuticals
• Bristol-Myers Squibb
• Catalyst Biosciences
• China Biologic Products
• Cosmo Pharmaceuticals
• Kamada
• King Pharmaceuticals
• Medxbio
• Merck
• Mitsubishi Tanabe Pharma
• Novo Nordisk
• Novozymes
• Portola Pharmaceuticals
• ProMetic Life Sciences
• rEVO Biologics
• Rockwell Medical
• Sanquin
• Shanghai RAAS
• Teva Pharmaceutical
• The Medicines Company
• Thermo Fisher Scientific
• Tianjin SinoBiotech & Beijing Bio-Fortune
• Ventria Bioscience

Market Characteristics

While entering the market or fighting the competition, understanding the market's momentum and challenges during the operation is important. The global Critical Care Therapeutics market has been moving haphazardly, making it difficult to trace this market's track and define the path concerning the future. Market trends, technological developments, and research & developments in the respective fields are among the major factors that require real-time surveillance to stay in touch with the success rate for which an appropriate report is required. All these points are carefully added to this report to ensure the success of the new and struggling market players.

Segment Assessment

In this well-connected world, the businesses are moving from local to global markets, which has increased the competition and is rising. For understanding the global Critical Care Therapeutics market, North America, Europe, Asia Pacific, and The Rest of the world are the major markets observed from 2020 to 2025. In this report, it is clearly defined that which region will hold the market share and will have the highest growth rate. Understanding the changes in governmental regulations and introducing new rules is also important to save the firm from any losses. This report covers all the challenges of this kind.

Research Methodology

The report on the global Critical Care Therapeutics market is prepared on Porter's Five Force Model and SWOT analysis. Porter's Five Force Model defines market competition, threats from new players, the threat from substitutes, suppliers' power, and customers' power. SWOT analysis defines strengths, weaknesses, opportunities, and threats included, which helps compile the complete report with high efficiency and dependency.

Enquiry About Report @ https://www.wiseguyreports.com/enquiry/1237686-global-critical-care-therapeutics-market-2017-2021

Table of Contents – Major Key Points

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Global critical care therapeutics: Market landscape

PART 06: Market segmentation by drug class

PART 07: Market segmentation by application

PART 08: Geographical segmentation

PART 09: Market drivers

PART 10: Market challenges

PART 11: Impact of drivers and challenges

Continued…

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here


Source: EIN Presswire

Alliance of Nurses for Healthy Environments Launches Climate Resources Amid Amy Coney Barrett’s Denial of Climate Change

Amid a battle for the Supreme Court, Alliance of Nurses for Healthy Environments (ANHE) released a new resource on how climate change is crucial to health.

WASHINGTON, DC, USA, October 20, 2020 /EINPresswire.com/ — Amid a heated battle for the Supreme Court nomination, the Alliance of Nurses for Healthy Environments (ANHE) has released a new resource that details how addressing climate change is crucial to health.

In recent comments about climate change during her confirmation hearings, Judge Amy Coney Barrett answered questions about her views on climate change — and she refused to agree that climate change is threatening clean air and water and referred to climate change as too “contentious” and “controversial” to weigh in on.

The climate crisis is not controversial for nurses, and it shouldn't be controversial for anyone. The science is clear, climate change is — simply put — a matter of public health. The wildfires, droughts, and hurricanes this year show that millions of Americans are suffering health problems from climate effects.

That is why as nurses currently fighting against the current climate crisis, we are calling on our policymakers to join us in taking strong action to address climate change. ANHE launched a new resource: Nurses’ Guide to What the Science Teaches Us about Common Solutions to Climate Change and Family Health Problems. The resource shares how addressing climate change will:

– Improve respiratory and cardiac health
– Protect outdoor workers from extreme heat
– Improve child and maternal health
– Improve mental health
– Improve neurological health

Solving the climate crisis is an essential component to addressing the institutionalized racism and health inequities that are amplified in the incidence and death statistics of the COVID-19 pandemic.

The communities most impacted by the coronavirus are also facing the greatest risk of health impacts from climate change—communities of color, low-income communities, people with pre-existing medical conditions, the elderly, and some essential workers. By tackling climate change, we have a powerful opportunity to significantly improve the health of these communities and create a healthier future for generations to come.

###

About ANHE: The Alliance of Nurses for Healthy Environments is the only national nursing organization focused solely on the intersection of health and the environment. The mission of the Alliance is to promote healthy people and healthy environments by educating and leading the nursing profession, advancing research, incorporating evidence-based practice, and influencing policy.

Cara Cook
ANHE
cara@envirn.org


Source: EIN Presswire

Angels of Las Vegas Wellness Walk

Angels of Las Vegas

Angels of Las Vegas kicks off Wellness Walk in Support of National Breast Cancer Awareness Month.

Cancer has affected so many of my friends and family. Maintaining a positive attitude along with exercising & healthy eating are the only things that can help us fight off all forms of Cancer,”

— stated Aynalem Workneh, AOLV President.

LAS VEGAS, NEVADA, USA, October 20, 2020 /EINPresswire.com/ — FOR IMMEDIATE RELEASE

Angels of Las Vegas
7836 W. Sahara Ave
Las Vegas Nevada, 89117
Phone: 1 (800) 214-9648
www.angelsoflv.org

Angles of Las Vegas kicks off Wellness Walk in Support of National Breast Cancer Awareness Month.

The Las Vegas-based non-profit wellness center brings emphasis to health and wellness in the community.

The Angels of Las Vegas Wellness Center is excited to announce their Wellness Walk to bring health and wellness awareness to the community. The Wellness Walk will be a live and virtual event held at Craig Ranch Regional Park on Saturday, October 24th from 8 AM to 11 AM.

“Cancer has affected so many of my friends and family. Maintaining a positive attitude along with exercising and healthy eating habits are the only things that can help us fight off not only COVID-19 but all forms of Cancer too,” stated Aynalem Workneh, AOLV President.

Due to COVID-19, the Angels of Las Vegas can only host 100 participants who will walk in the Wellness Walk; however, the public is virtually invited to participate in parks near their homes. This event will be live-streamed on their Facebook and YouTube Channel.

The Angels of Las Vegas Wellness Center urges women ages 40 years and older to talk with their doctors during National Breast Cancer Awareness month about breast cancer screening. Women who cannot afford mammograms may be eligible for free screening from a local health care provider.

The non-profit wellness center provides several programs for patients, survivors, caregivers, and families facing cancer and all types of life-threatening illnesses. The Angels of Las Vegas center offers a warm and inviting space for clients to relax, connect with others, and experience a sense of community. Services are provided by donations, ensuring that cost is not a barrier.

For more information or to donate online, please contact 1 (800) 214-9648 or visit angelsoflv.org.

PRESS CONTACT:
Rhonda Nolen
(702) 908-9577
rhonda@angelsoflv.org
###

ABOUT ANGELS OF LAS VEGAS
Angels of Las Vegas is a 501(c) 3 non-profit organization whose mission is to inspire and bring hope to those affected by all types of life-threatening illnesses. Founded in 2010, Angels of Las Vegas has grown over 20 members and has exceeded the boundaries of enhancing the quality of life for patients, caregivers, survivors, and families by providing free support, services, and education. Their programs include nutrition education, mindfulness, meditation, yoga, expressive arts, music therapy, and support group. Their programs aim to enhance an individual's ability to experience life quality through practices that provide stress management, reduce anxiety, relaxation techniques, and group exercise to incorporate physical, emotional, and spiritual well-being. Angels of Las Vegas offers a warm and inviting space for clients to relax, connect with others, and experience a sense of community. Services are provided by donations, ensuring that cost is not a barrier.

Rhonda Nolen
Angels of Las Vegas
+17028014327
Rhonda@angelsoflv.org
Visit us on social media:
Facebook


Source: EIN Presswire

Profiting from Misery: National Depression and Mental Health Screening Month

Americans, in comparison to other developed countries, use more medicines overall and rank first in the use of antipsychotics.

Americans, in comparison to other developed countries, use more medicines overall and rank first in the use of antipsychotics.

With more than 34 million Americans taking antidepressants in 2013-14, addiction and withdrawal from psychiatric is a growing problem.

With more than 34 million Americans taking antidepressants in 2013-14, addiction and withdrawal from psychiatric is a growing problem.

According to data taken from the IQVia Total Patient Tracker Database for Year 2019, extracted February 2020, 61,262 children between the ages of 0-5 years are prescribed antipsychotics in the US.

According to data taken from the IQVia Total Patient Tracker Database for Year 2019, extracted February 2020, 61,262 children between the ages of 0-5 years are prescribed antipsychotics in the US.

Millions of children are given psychiatric labels for normal childhood behavior and prescribed psychiatric drugs that drive them to commit violent acts and suicide.

Millions of children are given psychiatric labels for normal childhood behavior and prescribed psychiatric drugs that drive them to commit violent acts and suicide.

The headquarters for CCHR Florida are located in downtown Clearwater.

The headquarters for CCHR Florida are located in downtown Clearwater.

Mental health observances feed a $795 billion-dollar industry and are more about profit and less about helping those in need.

We are living in a drugged society that is blindly taking dangerous drugs such as antidepressants without fully understanding the risks.”

— Diane Stein, President CCHR Florida

CLEARWATER, FLORIDA, UNITED STATES, October 20, 2020 /EINPresswire.com/ — Each year the month of October is touted as National Depression and Mental Health Screening Month with the stated purposed to “bring awareness to the need for depression awareness and the need for accessible and affordable mental health screenings” and October 10th is recognized as World Mental Health Day.

However, the Citizens Commission on Human Rights (CCHR), a watchdog organization that investigates and exposes abuse in the mental health industry, believes such observances are less about helping people and more about profit.

According to CCHR International, “this year’s World Mental Health Day on October 10 was aimed at “increased investment in mental health,”[1] but failed to inform of the abuses prevalent in an already $795 billion per year industry, the mental health watchdog, Citizens Commission on Human Rights International warned.[2] The commemorative day was started by a group long-funded by pharmaceutical companies with an interest in increasing drug profits. The billions invested ignores the potential $32 billion in fraud committed and hundreds of thousands of patients, including children, abused and defrauded in the system each year.”

In order to raise awareness, the Florida chapter of CCHR is encouraging the general public to download free booklets on the common side effects of psychiatric drugs and to learn more about mental health screening.

Reports reveal that more than one‐in‐five adults were on at least one psychiatric drug in 2010, an increase of 22 percent from the year 2000 while more than a quarter of the adult female population is taking at least one psychiatric drug in the United States. [3]

Additionally, Americans, in comparison to other developed countries, use more medicines overall and rank first in the use of antipsychotics. [4] In the South Atlantic area of the country, which includes Florida, almost 18% [5] of the population is on at least one psychiatric drug and a report released in 2011 [6] from a two-year long investigation found that foster children in Florida were prescribed psychotropic drugs at rates 2.7 to 4.5 times higher than other children in Medicaid in 2008. [7]

“We are living in a drugged society that is blindly taking dangerous drugs such as antidepressants without fully understanding the risks,” said Diane Stein, President of CCHR Florida. “People need to be fully informed of the side effects associated with these drugs and the lack of science behind mental health screenings.” [8]

About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. L. Ron Hubbard, founder of Scientology, first brought psychiatric imprisonment to wide public notice: “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed. All in the name of ‘mental health,’” he wrote in March 1969. For more information visit www.cchrflorida.org or call 800-782-2878.

Sources:
[1] https://www.who.int/campaigns/world-mental-health-day/world-mental-health-day-2020
[2] “The global psychiatrist market was valued at $795.1 billion in 2017,” PR Newswire, 10 Dec. 2018, https://www.prnewswire.com/news-releases/the-global-psychiatrist-market-was-valued-at-795-1-billion-in-2017–300762788.html
[3] https://www.foxnews.com/health/one-in-five-american-adults-takes-psychiatric-drugs
[4] http://www.pbs.org/newshour/updates/americans-spend-much-pharmaceuticals/
[5] https://www.foxnews.com/health/one-in-five-american-adults-takes-psychiatric-drugs
[6] http://www.gao.gov/new.items/d12270t.pdf
[7] http://www.npr.org/sections/health-shots/2011/12/01/143017520/foster-kids-even-infants-more-likely-to-be-given-psychotropic-drugs
[8] https://www.cchrflorida.org/watchdog-calls-into-question-reliance-on-risk-assessments-during-suicide-awareness-month/

Diane Stein
Citizens Commission on Human Rights of Florida
+1 727-422-8820
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Voices for Humanity – Diane Stein Takes On The Psychiatric & Pharmaceutical Industries


Source: EIN Presswire

SCHREMS II WEBINAR FAQ #3: Do Additional Safeguards enable Schrems II compliant EU employee data processing?

Schrems II Webinar FAQ 3 of 25: Do Additional Safeguards enable Schrems II compliant EU employee data processing?

Schrems II Webinar FAQ 3 of 25: Do Additional Safeguards enable Schrems II compliant EU employee data processing?

Anonos: Maximizing Data Liquidity – Universal Protection & Unrivaled Utility

Anonos: Maximizing Data Liquidity – Universal Protection & Unrivaled Utility

Yes. If you are already practicing Data Protection by Design and By Default.

BRUSSELS, BELGIUM, October 20, 2020 /EINPresswire.com/ — Schrems II Webinar FAQ #3 of 25: Do Additional Safeguards enable Schrems II compliant EU employee data processing?

Yes. If you are already practicing Data Protection by Design and By Default, most employee-related processing involving EU personal data can continue using additional safeguards like GDPR-heightened Pseudonymisation.

NOTE: Answers to numerous questions related to the ability of Pseudonymisation and Data Protection by Design and by Default to enable EU employee-related processing – both in the context of Schrems II compliance purposes and generally – were combined in the following.

Limitations of Consent and Contract for EU Employee Data Processing

Unlike many other use cases, consent-based processing will rarely be an option for employee-related data (1). This is because of the imbalance of power between employers and employees; employees can only freely give consent in exceptional circumstances. It is extremely difficult for employers to rely on the lawful basis of consent to process employees’ personal data (2).

With consent generally not available, attention naturally turns to contract-based processing. However, in that case processing is limited to what is strictly necessary for the performance of the contract (3). In the employment context, this might cover payroll and benefits administration, but cannot extend to secondary uses like Talent Analytics. Moreover, the use of contract does not constitute an additional safeguard that would enable international transfer of this data for processing outside the EU for the same reasons SCCs alone are now inadequate – government agencies that might surveill the data are not bound by the contract.

As discussed in the webinar, one of the consequences of the Data Protection by Design and by Default (DPbDD) obligations under Article 25 of the GDPR is that if processing can be done using de-identified data it must be. Note that this is true whether processing is done within the EU (localised), or outside the EU. Using GDPR pseudonymisation to de-identify data can be quite useful in establishing the grounds for processing based on legitimate interests.

Legitimate Interest Processing for EU Employee Data

Using a technical and organisation safeguard like GDPR heightened Pseudonymisation can “tip the balance in favour of the controller” so that employee data can be processed under legitimate interests grounds under the GDPR (4). And, if a Data Protection Impact Assessment is performed along these lines prior to export to a non-EU processor, with only the EU exporter retaining the ability to relink to employee identity, this can satisfy Schrems II requirements to allow processing to continue both inside and outside of the EU.

Schrems II Compliant Processing of EU Employee Data Using DPbDD

Many high value uses of EU employee data, like Talent Analytics, can be done in compliance with DPbDD obligations by using de-identified data. Where processing cannot be done using de-identified data, processing is likely to have to be localized, and limited to what can be performed pursuant to performance of a contract. This is because, in the case of international transfers, of the obvious inability to limit parties other than an EU exporter to identify the data subjects, and, in the case of localized processing, of the difficulty of meeting the requirements for legitimate interests processing on identifiable data.

As always, the practicality of DPbDD in a specific situation will be determined by non-privacy related legal requirements applicable to the situation (e.g., employment requirements) but this question provides a good opportunity to review some underlying principles of DPbDD.

Potential DPbDD Approaches

The following three DPbDD options, among others, may be available.

Option No 1:

The identity of the individual could be de-identified by replacing their name and other identifying information with a random pseudonym (we will refer to this pseudonym as “RP1” for Random Pseudonym One) that could be randomly assigned and not derived from the underlying data so that it would not be susceptible to re-identification if intercepted (see https://en.wikipedia.org/wiki/One-time_pad). RP1 could be used to refer to the individual rather than the identifying information. The EU Employer/Exporter could hold the GDPR Article 4(5) “additional information” that is necessary to attribute the RP1 pseudonym to the specific data subject. Care would need to be taken not to use the same RP1 pseudonym to the point that unauthorized third parties could infer, single out or link the RP1 pseudonym to the individual without requiring access to the additional information held separately by the EU Employer/Exporter. Different pseudonyms could be used at different times for different purposes, with the “additional information” necessary to attribute the different pseudonyms to the same individual held by the EU Employer/Exporter.

Option No. 2:

The employee information exported by the EU Employer/Exporter could be aggregated into a format that enables desired processing at a small cohort or “look-alike” group level; only the defined cohort values would be provided to the data importer for processing. Cohorts must be small enough to represent the distinct characteristics, attributes, preferences, activities, behaviours and even location of a real group of data subjects necessary to achieve business objectives from processing data, but large enough that they don’t enable singling out, linking to, or inferences about the identity of individual data subjects (5). This balance can be hard to strike without applying technical measures to reduce re-identification likelihood. Upon receipt of the results of processing by the data importer, the EU Employer/Exporter can then re-link the information to the appropriate employee data using the “additional information that they possess and maintain exclusively in the EU.

Option No. 3:

When there are insufficient numbers of EU employees to create the cohorts suggested in Option No 2 above, synthetic data can be added to the data provided to the data importer which represents fictitious employees while ensuring that the important statistical properties of the sample data are reflected in synthetic data.

Summary

Although consent may be an option in some cases for non-EU based processing of EU personal data, it is rarely available as a basis for processing employee data, and so is not relevant as a Schrems II solution. Contract has very narrow applicability to only specific types of administrative processing and does not address Schrems II requirements for additional safeguards that ensure protection against surveillance. However, where processing of employee data can be done in de-identified form, GDPR pseudonymisation has the three-fold benefit of:

Supporting DPbDD requirements;
Assisting in meeting the requirements for legitimate interests processing; and
Serving as an additional safeguard to help meet Schrems II requirements.

*******
The Schrems II Webinar – Lawful Data Transfer – with NOYB, EDPS and industry experts was held on 8 October 2020. Over 2,300 registered and submitted over 900 questions. These 900+ questions were distilled down to the top 25 Frequently Asked Questions (FAQs). These FAQs are being posted to the LinkedIn Schrems II group for comments by the community and at SchremsII.com/FAQs. If you are not already a member of the Schrems II LinkedIn group, we encourage you to join to learn and participate in the discussion. A summary, transcript and replay of the webinar can be viewed at SchremsII.com/learn.

******
(1) See Section 3.1.1 in Guidelines on Consent under Regulation 2016/679 (wp259rev.01) available at https://ec.europa.eu/newsroom/article29/item-detail.cfm?item_id=623051 at page 6.
(2) https://www.cooleygo.com/gdpr-a-guide-for-employers/
(3) See Section III.2.2 of Opinion 06/2014 on the Notion of Legitimate Interests https://ec.europa.eu/justice/article-29/documentation/opinion-recommendation/files/2014/wp217_en.pdf at page 16.
(4) See Section III.3 of Opinion 06/2014 on the Notion of Legitimate Interests https://ec.europa.eu/justice/article-29/documentation/opinion-recommendation/files/2014/wp217_en.pdf at page 23 – 43.
(5) For example, see https://www.anonos.com/variant-twin-value-proposition

Schrems II FAQs from
Anonos
email us here

SCHREMS II WEBINAR FAQ #3: Do Additional Safeguards enable Schrems II compliant EU employee data processing?


Source: EIN Presswire